Thelansis

Macular Telangiectasia Type 2 Market Outlook Thelansis’s “Macular Telangiectasia Type 2 Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Macular Telangiectasia Type 2 treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on t...

  Macular Telangiectasia Type 2 Market Outlook Thelansis’s “Macular Telangiectasia Type 2 Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Macular Telangiectasia Type 2 treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Macular Telangiectasia Type 2 Overview Macular telangiectasia (MacTel) type 2 is a bilateral retinal disorder of unknown etiology, characterized by distinct alterations in the macular capillary network and neurosensory atrophy. Initially, the disease manifests temporally to the foveal center and may expand to encompass an oval region with approximate dimensions of 6° horizontally and 5° vertically centered on the fo...

  Macular telangiectasia (MacTel) type 2 is a bilateral retinal disorder of unknown etiology, characterized by distinct alterations in the macular capillary network and neurosensory atrophy. Initially, the disease manifests temporally to the foveal center and may expand to encompass an oval region with approximate dimensions of 6° horizontally and 5° vertically centered on the foveola. The onset of symptoms typically occurs during the fifth or sixth decade of life, and a subset of patients reports a positive family history. Due to limited awareness among both clinicians and patients, MacTel type 2 is often diagnosed belatedly and may be misidentified as age-related macular degeneration in cases involving neovascularization. The prevalence of MacTel type 2 is rare, estimated at approximately 0.10%, with no significant gender or racial predilections. The mean age of onset is approximately 55 years. Notably, up to 45% of individuals with MacTel type 2 also present with comorbid cond...